i agree, i don't think the FDA is in the clear as
Post# of 148286
as for the DSMC, i think they are appointed by the sponsor and I don't think the FDA has much to do with that. I have no idea why they are not given the power to look closer at the trial and why they did not see the problems, it could be when they looked, everything was good. after that is when we really started pushing to get fully enrolled and that might have been when the wrong patient skew took place. Again, this was an Amarex screw up because Cytodyn started sending our employee out to help with recruitment when that was Amarex's job. We were also competing with every other drug trial going on. Stopping compassionate use was part of this, if patient had the choice of life saving drug from compassionate use or possibly getting placebo, they chose compassionate use. Closing this was an attempt to get the trial enrolled.